Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
DALY 2-EU
Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
- NCT04844866 ↗
- Recruiting
- Miltenyi Biomedicine GmbH
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 7 | |
| Podcasts | 3 | |
| X threads | 2 |
The trial
ClinicalTrials.gov- Official title
- A Pivotal Phase II Randomised, Multi-centre, Open-label Study to Evaluate the Efficacy and Safety of MB-CART2019.1 Compared to SoC Therapy in Participants With r/r DLBCL, Who Are Not Eligible for HDC and ASCT
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- MB-CART2019.1; Standard of Care
- Arms
- Part I: CAR T-cell MB-CART2019.1 · Experimental
- Part II: CAR T-cell MB-CART2019.1 · Experimental
- PART I: Standard of Care · Active comparator
- Enrollment
- 213 (estimated)
- Primary outcomes
- Part I: Event-free survival
- Part II: Best objective response rate
- Sponsor
- Miltenyi Biomedicine GmbH with ICON plc
- Start
- Aug 18, 2021
- Primary completion
- Jan 15, 2025
- Results posted
- No
- Registry record
- NCT04844866 · updated Jun 10, 2026